0.6052
price up icon4.15%   0.0241
after-market 시간 외 거래: .59 -0.0152 -2.51%
loading
전일 마감가:
$0.5811
열려 있는:
$0.598
하루 거래량:
481.22K
Relative Volume:
0.69
시가총액:
$35.53M
수익:
-
순이익/손실:
$-41.95M
주가수익비율:
-0.1691
EPS:
-3.58
순현금흐름:
$-38.34M
1주 성능:
+4.29%
1개월 성능:
+3.42%
6개월 성능:
-83.77%
1년 성능:
+28.55%
1일 변동 폭
Value
$0.5713
$0.6178
1주일 범위
Value
$0.5221
$0.6178
52주 변동 폭
Value
$0.4401
$5.8299

Elevation Oncology Inc Stock (ELEV) Company Profile

Name
명칭
Elevation Oncology Inc
Name
전화
(716) 371-1125
Name
주소
101 FEDERAL STREET, BOSTON
Name
직원
29
Name
트위터
Name
다음 수익 날짜
2024-08-05
Name
최신 SEC 제출 서류
Name
ELEV's Discussions on Twitter

ELEV을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
ELEV 0.6052 35.53M 0 -41.95M -38.34M -3.58
VRTX 450.37 115.10B 10.63B -479.80M -1.35B 13.33
REGN 744.50 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 596.74 35.07B 1.86B -40.29M -1.28B -4.16
ALNY 246.80 32.20B 2.09B -332.26M 16.06M -4.14
BNTX 108.23 25.09B 3.30B -501.07M 1.03B 11.54

Elevation Oncology Inc Stock (ELEV) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2021-12-23 개시 H.C. Wainwright Buy

Elevation Oncology Inc 주식(ELEV)의 최신 뉴스

pulisher
Nov 15, 2024

Logos Global Management LP Adjusts Stake in Elevation Oncology I - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

OrbiMed Advisors LLC Increases Stake in Elevation Oncology Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 12, 2024

Elevation Oncology's SWOT analysis: promising ADC stock faces key data readout - Investing.com

Nov 12, 2024
pulisher
Nov 07, 2024

Goldman Sachs Group Inc's Strategic Acquisition in Elevation Onc - GuruFocus.com

Nov 07, 2024
pulisher
Nov 06, 2024

Elevation Oncology’s Q3 2024 Highlights and Financial Report - TipRanks

Nov 06, 2024
pulisher
Nov 06, 2024

Elevation Oncology's Cancer Drug Shows 43% Response Rate, Secures FDA Fast Track | ELEV Stock News - StockTitan

Nov 06, 2024
pulisher
Nov 06, 2024

Elevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Achievements - PR Newswire

Nov 06, 2024
pulisher
Nov 05, 2024

Ovarian Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail

Nov 05, 2024
pulisher
Nov 05, 2024

Vanguard Group Inc's Strategic Acquisition in Elevation Oncology Inc - GuruFocus.com

Nov 05, 2024
pulisher
Oct 25, 2024

Alkermes' Q3 Earnings & Revenues Fall Shy Of Estimates, Stock Down - Barchart

Oct 25, 2024
pulisher
Oct 22, 2024

AstraZeneca Receives CHMP's Approval for Wainzua in Europe - Zacks Investment Research

Oct 22, 2024
pulisher
Oct 22, 2024

EDIT Inks Collaboration Deal to Develop Novel Gene Editing Therapies - Yahoo Canada Finance

Oct 22, 2024
pulisher
Oct 19, 2024

SNY Inks Deal With Orano Med for Next-Generation Radioligand Therapies - MSN

Oct 19, 2024
pulisher
Oct 17, 2024

GSK's NDA for UTI Drug Gepotidacin Gets FDA's Priority Review - MSN

Oct 17, 2024
pulisher
Oct 16, 2024

Is Elevation Oncology Inc (ELEV) worth investing in despite its overvalued state? - US Post News

Oct 16, 2024
pulisher
Oct 14, 2024

Trading Day Review: Elevation Oncology Inc (ELEV) Gains Momentum, Closing at 0.51 - The Dwinnex

Oct 14, 2024
pulisher
Oct 14, 2024

It is Poised to be a Bull Market for Elevation Oncology Inc (ELEV) - SETE News

Oct 14, 2024
pulisher
Oct 11, 2024

Elevation Oncology Inc (ELEV)’s stock price range in the last year - US Post News

Oct 11, 2024
pulisher
Oct 10, 2024

What Makes Elevation Oncology (ELEV) a New Strong Buy Stock - MSN

Oct 10, 2024
pulisher
Oct 09, 2024

Empery Asset Management's Strategic Acquisition in Elevation Oncology - Yahoo Finance

Oct 09, 2024
pulisher
Oct 09, 2024

In the Green: Elevation Oncology Inc (ELEV) Closes at 0.52, Up/Down -3.69 from Previous Day - The Dwinnex

Oct 09, 2024
pulisher
Oct 04, 2024

Taking on analysts’ expectations and winning: Elevation Oncology Inc (ELEV) - SETE News

Oct 04, 2024
pulisher
Sep 30, 2024

Affimed Appoints New CEO, Shares Fall on Leadership Change - MSN

Sep 30, 2024
pulisher
Sep 30, 2024

Market Momentum Report: Elevation Oncology Inc (ELEV)’s Positive Close at 0.59 - The Dwinnex

Sep 30, 2024
pulisher
Sep 30, 2024

Elevation Oncology's SWOT analysis: promising ADC stock faces key data readouts - Investing.com

Sep 30, 2024
pulisher
Sep 30, 2024

Should investors be concerned about Elevation Oncology Inc (ELEV)? - US Post News

Sep 30, 2024
pulisher
Sep 26, 2024

Elevation Oncology Inc (ELEV) Stock: The Story of a 52-Week Stock Range - The InvestChronicle

Sep 26, 2024
pulisher
Sep 24, 2024

Elevance Health Inc [ELV] PERU RAMIRO G sells 753 Shares for $0.4 million - Knox Daily

Sep 24, 2024
pulisher
Sep 24, 2024

Check out these key findings about Elevation Oncology Inc (ELEV) - SETE News

Sep 24, 2024
pulisher
Sep 24, 2024

Lombard Odier Asset Management Europe Ltd Invests $2.51 Million in Elevance Health, Inc. (NYSE:ELV) - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

FDA grants fast track designation for Elevation Oncology’s EO-3021 - Pharmaceutical Business Review

Sep 24, 2024
pulisher
Sep 24, 2024

Pacer Advisors Inc. Decreases Stock Position in Elevance Health, Inc. (NYSE:ELV) - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Distillate Capital Partners LLC Grows Position in Elevance Health, Inc. (NYSE:ELV) - MarketBeat

Sep 24, 2024
pulisher
Sep 23, 2024

Study Underscores Importance of Medicaid Coverage for Pregnant Women - Healthcare Innovation

Sep 23, 2024
pulisher
Sep 23, 2024

Elevai Labs shares tumble on pricing of new stock offering - The Business Journals

Sep 23, 2024
pulisher
Sep 23, 2024

Elevance Health, Inc. (NYSE:ELV) Position Boosted by Magnetar Financial LLC - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Decoding Elevance Health's Options Activity: What's the Big Picture? - Benzinga

Sep 23, 2024
pulisher
Sep 23, 2024

ELAB’s price-to-free cash flow ratio: What it means for investors - US Post News

Sep 23, 2024
pulisher
Sep 23, 2024

Ratios in Focus: Analyzing Elevation Oncology Inc (ELEV)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Sep 23, 2024
pulisher
Sep 23, 2024

Why Elevai Labs (ELAB) Stock Is Down 60% Today - Benzinga

Sep 23, 2024
pulisher
Sep 23, 2024

Investing in Elevation Oncology Inc (ELEV) might be a great opportunity, but the stock is a bit undervalued - US Post News

Sep 23, 2024
pulisher
Sep 23, 2024

Baltic Fintech Eleving To Raise Up To €30M In IPO - Law360

Sep 23, 2024
pulisher
Sep 23, 2024

FDA grants fast track to Elevation Oncology's cancer drug - Investing.com

Sep 23, 2024
pulisher
Sep 23, 2024

Ensign Peak Advisors Inc Acquires 2,862 Shares of Elevance Health, Inc. (NYSE:ELV) - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Elevai Labs Inc. Announces Pricing of $8.0 Million Public Offering - GlobeNewswire

Sep 23, 2024
pulisher
Sep 23, 2024

Elevation Oncology Gets FDA Fast-Track Designation for EO-3021 - MarketWatch

Sep 23, 2024
pulisher
Sep 23, 2024

Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2 - StockTitan

Sep 23, 2024
pulisher
Sep 23, 2024

Eleving Group Targets $34 Million From Initial Public Offering - MarketWatch

Sep 23, 2024
pulisher
Sep 22, 2024

Fidelis Capital Partners LLC Acquires 1,168 Shares of Elevance Health, Inc. (NYSE:ELV) - Defense World

Sep 22, 2024
pulisher
Sep 22, 2024

1832 Asset Management L.P. Sells 5,622 Shares of Elevance Health, Inc. (NYSE:ELV) - Defense World

Sep 22, 2024
pulisher
Sep 22, 2024

Frank Rimerman Advisors LLC Raises Stock Position in Elevance Health, Inc. (NYSE:ELV) - Defense World

Sep 22, 2024

Elevation Oncology Inc (ELEV) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$70.39
price down icon 0.93%
$18.42
price down icon 1.07%
$38.25
price up icon 3.55%
$367.36
price up icon 0.83%
$194.56
price up icon 0.15%
$108.23
price up icon 5.96%
자본화:     |  볼륨(24시간):